Academic Appointments:
Division of Endocrinology
and Molecular Medicine
Cardiovascular Research
Center
Graduate Center for
Nutritional Sciences
Department of Internal
Medicine
Education:
MD, University of Hamburg,
Germany
Doctoral Thesis (magna cum
laude), University of
Hamburg, Germany
Residency Internal
Medicine/Cardiology,
Humboldt University Berlin,
Charité Hospital in
Collaboration with the
German Heart Institute,
Germany
Fellowship, Division of
Endocrinology, Diabetes and
Hypertension, University of
California, Los Angeles
Clinical Interests:
Dr. Bruemmer has special
interest in Preventive
Medicine and Cardiovascular
Risk Factor reduction
including the treatment of
Type 2 Diabetes,
Hyperlipidemia, and
Hypertension.
Research Interests:
Cardiovascular disease is
the leading cause of death
in the nation and
industrialized nations,
accounting for nearly 50% of
all deaths. Particularly,
diabetes is associated with
significantly accelerated
rates of
cardiovascular
complications. According to
the Center for Disease
Control and Prevention 18.3
% of all people age 60 years
or older had diabetes in
2002 and an estimated 65 %
of patients with diabetes
ultimately die from
cardiovascular causes.
With the recognition of this
evidence, understanding the
mechanisms leading to
diabetic vascular
complications has become a
focus of our research
laboratory. We are
particularly interested in
characterizing the molecular
pathways by which members of
the nuclear hormone
receptors superfamily such
as the peroxisome
proliferator-activated
receptor-gamma (PPARg)
or Liver X Receptors (LXR)
suppress the expression of
genes involved in the
development of
cardiovascular disease in
diabetes.
Our laboratory has
primarily focused on
understanding the regulation
of vascular smooth muscle
cell proliferation and
inflammation by these
receptors. Understanding
these mechanisms is of
considerable interest as
these nuclear transcription
factors can be
pharmacologically activated
by agents already clinically
used to treat
insulin-resistance in
patients with type 2
diabetes and dyslipidemia,
two of the most common
cardiovascular risk factors.
Since these drugs are
currently being further
investigated in large
randomized trials for their
efficacy to prevent
cardiovascular disease, our
research might point to
molecular mechanisms by
which these agents prevent
the development of
cardiovascular complications
in patients with diabetes.
Awards:
Research Fellowship Acute
Coronary Syndrome, German
Society of Cardiology
Gonda (Goldschmied) Diabetes
Center Research Fellowship,
University of California,
Los Angeles
Finalist AstraZeneca
Cardiovascular Young
Investigators Forum
New Investigator Award,
Council for High Blood
Pressure Research, American
Heart Association
Young Investigator Award
Basic Science (1. Prize),
European Society of
Cardiology
Young Investigator Award,
The Endocrine Society
ATVB Merit Award for Young
Investigators,
Council on Arteriosclerosis,
Thrombosis, and Vascular
Biology, American Heart
Association
Pilot and Feasibility Grant
Award, University of
California, Los Angeles and
San Diego
Young Scholar Award,
American Society of
Hypertension
National Scientist
Development Grant, American
Heart Association
Physician-Scientist Award,
University of Kentucky
Irvine H. Page Young
Investigator Research Award,
Council on Arteriosclerosis,
Thrombosis and Vascular
Biology, American Heart
Association.
Representative Publications:
1.
Brummer D, Evans
D, Berg D, Greten H,
Beisiegel U, Mann WA.
Expression of type III
hyperlipoproteinemia in
patients homozygous for
apolipoprotein E-2 is
modulated by lipoprotein
lipase and postprandial
hyperinsulinemia. J Mol Med
1998; 76: 355-364
2. Goetze S, Blaschke F,
Stawowy P,
Bruemmer D,
Spencer C, Graf K, Grafe M,
Law RE, Fleck E. TNFalpha
inhibits insulin's
antiapoptotic signalling in
vascular smooth muscle
cells. Biochem Biophys Res
Commun 2001; 287: 662-70
3.
Bruemmer D,
Riggers U, Holzmeister J,
Ludewig B, Grill M, Lippek
F, Settmacher U,
Regitz-Zagrosek V, Fleck E,
Graf K. Expression of CD40
in vascular smooth muscle
cells and macrophages is
associated with the early
development of human
atherosclerotic lesions. Am
J Card 2001; 87: 21-7
4. Knecht M, Pagel I,
Langenickel T, Philipp S,
Scheuermann-Freestone M,
Willnow T,
Bruemmer D, Graf
K, Dietz R, Willenbrock R.
Increased expression of
renal neutral endopeptidase
in severe heart failure.
Life Sci 2002;
71: 2701
5. Kintscher U, Lyon C,
Wakino S,
Bruemmer D, Feng
X, Goetze S, Graf inhibits
TGF-ßaK,
Moustakas A, Staels B, Fleck
E, Hsueh WA, Law RE. PPAR
induced ß5 Integrin
Transcription in vascular
smooth muscle cells by
interacting with Smad4.
Circ Res. 2002;
91:35-44.
6. Kintscher U, Wakino S,
Bruemmer D,
Goetze S, Graf K, Hsueh W.A,
Law RE. TGF-beta(1) induces
peroxisome
proliferator-activated
receptor gamma1 and gamma2
expression in human THP-1
monocytes.
Biochem Biophys Res Commun.
2002; 297: 794-9
7.
Bruemmer D, Yin
F, Liu J, Kiyono T, Fleck E,
Van Herle A, Graf K, Law RE.
Atorvastatin inhibits
expression of minichromosome
maintenance proteins in
vascular smooth muscle
cells.
Eur J Pharmacol.
2003;462:15-23.
8.
Bruemmer D,
Berger JP, Liu J, Kintscher
U, Wakino S, Fleck E, Moller
D, Law RE. A
Non-Thiazolidinedione
Partial Peroxisome Ligand
Inhibits Vascular Smooth
Muscle CellgProliferator-activated
Receptor Growth.
Eur J Pharmacol.
2003; 466 :225-234.
9.
Bruemmer D, Yin
F, Liu J, Kiyono T, Fleck E,
Van Herle A, Law R.
Rapamycin inhibits
E2F-dependent Expression of
Minichromosome Maintenance
Proteins in Vascular Smooth
Muscle Cells.
Biochem Biophys Res Commun.
2003; 303:251-8.
10. De Dois, ST,
Bruemmer D,
Dilley, RJ, Jennings, GLR,
Law, ligandsgRE,
Little P. Inhibitory
activity of clinical
thiazolidinedione PPAR
toward cultured internal
mammary artery, radial
artery and saphenous vein
smooth muscle cells.
Circulation.
2003; 107:2548-50.
11. Kintscher U,
Bruemmer D,
Blaschke F, Unger T, Law RE.
p38 MAP kinase negatively
regulates angiotensin
II-mediated effects on cell
cycle molecules in human
coronary smooth muscle
cells.
Biochem Biophys Res Commun.
2003; 305:552-556
12. Eibl G,
Bruemmer D, Okada
Y, Duffy JP, Law RE, Reber
HA, Hines OJ. PGE2
is generated by specific
COX-2 activity and increases
VEGF production in COX-2
expressing human panceatic
cancer cells.
Biochem Biophys Res Commun.
2003; 306:887-97.
13.
Bruemmer D, Yin
F, Liu J, Berger JP, Kiyono
T, Chen J, Fleck E, Van
Herle A, Forman BM, Law RE.
Peroxisome Inhibits
Expression of MinichromosomegProliferator-activated
Receptor Maintenance
Proteins in Vascular Smooth
Muscle Cells.
Mol Endocrinol.
2003; 17:1005-18
14.
Bruemmer D, Yin
F, Liu J, Berger JP, Sakai
T, Chen J, Fleck E, Van
Herle A, Forman BM, Law RE.
Regulation of the growth
arrest and DNA
damage-inducible gene 45
(GADD45) by Peroxisome in
Vascular Smooth Muscle
Cells.gProliferator-activated
Receptor
Circ Res. 2003;
93:38-47
15.
Bruemmer D, Yin
F, Liu J, Kiyono T, Fleck E,
Van Herle A, Law RE.
Expression of Minichromosome
Maintenance Proteins in
Vascular Smooth Muscle Cells
is ERK/MAPK-dependent.
Exp Cell Res.
2003; 290:28-37
16.
Bruemmer D,
Collins AR, Noh G, W. W,
Territo M, Arias-Magallona
S, Fishbein MC, Kintscher U,
Fleck E, Law RE, Hsueh WA.
Angiotensin II Accelerated
Atherosclerosis is
Attenuated in Osteopontin
Deficient Mice.
J Clin Invest.
2003;112:1318-31.
17.
Bruemmer D, Law
RE.
Thiazolidinediones and
Regulation of Smooth Muscle
Cell Proliferation.
American Journal of Medicine.
2003; 114 Suppl 8A: 87S-92S.
18. Hsueh WA,
Bruemmer, D:
Implications forg.
PPAR Cardiovascular Disease.
Hypertension,
2004; 43:297-305.
19. Yin F,
Bruemmer D,
Blaschke F, Hsueh WA, Law
RE, Van Herle AJ. Signaling
Pathways Involved in
Induction of GADD45 Gene
Expression and Apoptosis by
Troglitazone in Human MCF-7
Breast Carcinoma Cells.
Oncogene, 2004;
23(26):4614-23.
20. Collins AR, Schnee J,
Wang W, Kim S, Fishbein MC,
Bruemmer D, Law
RE, Nicholas S, Ross RS,
Hsueh WA. Osteopontin
modulates AngII-induced
fibrosis in the intact
murine heart.
J Am Coll Cardiol,
2003; 43(9):1698-705.
21. Blaschke F,
Bruemmer D, Yin
F, Takata Y, Wang W,
Fishbein MC, Okura T, Higaki
J, Graf K, Fleck E, Hsueh
WA, Law RE. C-reactive
protein induces apoptosis in
human coronary vascular
smooth muscle cells.
Circulation,
2004; 110(5):579-87
22. Blaschke F,
Bruemmer D, Law
RE. Egr-1 is a Major
Vascular Pathogenic
Transcription
Factor in Atherosclerosis
and Restenosis.
Rev in Endocr Metab Disord,
2004; 5(3):249-54
23. Blaschke F,
Bruemmer D, Law
RE. Will the potential of
peroxisome
proliferator-activated
receptor agonists be
realized in the clinical
setting? Clin Cardiol. 2004,
(7 Suppl 4):IV3-10.
24. Blaschke F, Leppaenen O,
Takata Y, Caglayan E, Liu J,
Fishbein MC, Kappert K,
Nakayama KI, Fleck E, Hsueh
WA, Law RE,
Bruemmer D. Liver
X Receptor Agonists Suppress
Vascular Smooth Muscle Cell
Proliferation and Inhibit
Neointima Formation in
Balloon-Injured Rat Carotid
Arteries.
Circ Res. 2004;
95(12):e110-23.
25.
Bruemmer D,
Blaschke F, Law RE. New
Targets for peroxisome
proliferator activated
receptor {gamma} in the
Vessel Wall: Implications
for Restenosis.
Int J Obes Relat Metab
Disord, 2005,
29:26-30
26. Ogawa D, Stone JF,
Takata Y, Blaschke F, Chu
VH, Towler DA, Law RE, Hsueh
WA,
Bruemmer D.
Liver X Receptor Agonists
inhibit cytokine-induced
Osteopontin Expression in
Macrophages through
Interference with Activator
Protein-1 Signaling
Pathways.
Circ Res. 2005,
96:59-67.
|
